Significant Ownership of Affinity Asset Advisors, LLC
- Signature - Title
- /s/ Andrew Weinstein - Andrew Weinstein, Chief Financial Officer and Chief Compliance Officer
- Location
- New York, NY
- Summary
- This page shows a list of all the recent SCHEDULE 13D/G filings made by Affinity Asset Advisors, LLC.
Follow Filing Activity
Follow Affinity Asset Advisors, LLC and return when a new Schedule 13D/G filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
CIK context first
Continue from Affinity Asset Advisors, LLC
Significant Ownership of Affinity Asset Advisors, LLC
| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| IBIO | iBio, Inc. | Common Stock, par value $0.001 per share | 10% | $7,675,906 | +$2,392,350 | 3,489,048 | +45% | Affinity Asset Advisors, LLC | 31 Mar 2026 |
| NXTC | NextCure, Inc. | Common Stock, $0.001 par value per share | 10% | $4,375,018 | +$1,966,899 | 348,607 | +82% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| OVID | Ovid Therapeutics Inc. | Common Stock, par value $0.001 per share | 9.1% | $45,030,194 | +$10,040,596 | 15,635,484 | +29% | Affinity Asset Advisors, LLC | 31 Mar 2026 |
| VTYX | Ventyx Bioscience, Inc. | Common Stock, $0.0001 par value per share | 9% | $58,381,906 | +$21,744,625 | 6,465,041 | +59% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| STRO | Sutro Biopharma, Inc. | Common Stock, $0.001 par value per share | 8.8% | $8,444,817 | 748,382 | Affinity Asset Advisors, LLC | 22 Jan 2026 | ||
| KPTI | Karyopharm Therapeutics Inc. | Common Stock, $0.0001 par value per share | 8.6% | $12,870,974 | +$7,880,460 | 1,713,092 | +158% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| KPTI | Karyopharm Therapeutics Inc. | Common Stock, $0.0001 par value per share | 8.6% | $1,244,110 | 2,073,517 | Affinity Asset Advisors, LLC | 31 Mar 2026 | ||
| FBRX | Forte Biosciences, Inc. | Common Stock, par value $0.001 per share | 7.3% | 1,011,890 | Affinity Asset Advisors, LLC | 31 Mar 2026 | |||
| LXEO | Lexeo Therapeutics, Inc. | Common Stock, $0.0001 par value per share | 7.1% | $51,813,451 | +$9,589,340 | 5,217,660 | +23% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| HLXC | Helix Acquisition Corp. III | Class A ordinary shares, par value $0.0001 per share | 7% | $12,700,000 | 1,250,000 | Affinity Asset Advisors, LLC | 31 Mar 2026 | ||
| FBRX | Forte Biosciences, Inc. | Common Stock, par value $0.001 per share | 6.7% | $22,251,791 | -$731,169 | 834,964 | -3.2% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| STRO | Sutro Biopharma, Inc. | Common stock, $0.001 par value per share | 6.5% | $26,642,467 | -$137,363,902 | 1,069,519 | -84% | Affinity Asset Advisors, LLC | 31 Mar 2026 |
| AVTX | Avalo Therapeutics, Inc. | Common Stock, $0.001 par value per share | 5.5% | $19,321,504 | +$4,175,816 | 1,340,840 | +28% | Affinity Asset Advisors, LLC | 31 Mar 2026 |
| VRCA | Verrica Pharmaceuticals Inc. | Common Stock, $0.0001 par value per share | 5.5% | $7,346,762 | 884,172 | 0% | Affinity Asset Advisors, LLC | 22 Jan 2026 | |
| INZY | Inozyme Pharma, Inc. | Common Stock, par value $0.0001 per share | 2.9% | $2,203,898 | 1,867,710 | Affinity Healthcare Fund, LP | 20 May 2025 |
Schedules 13D/G Reported by Affinity Asset Advisors, LLC:
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Filing Date |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.